Registered title, quoted from ClinicalTrials.gov
Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
An open trial on neuroblastoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 1 other hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteDongguan Taixin Hospital东莞台心医院DongguanHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06836505, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
1 year to 50 years; sex: all
Registered eligibility fields
Patients who have received radiation therapy within 2 weeks prior to infusion;
Exclusion criterion 3
Karnofsky performance status (for patients ≥16 years) or Lansky performance status (for patients <16 years) (Appendix 1) must be at least 50;
Inclusion criterion 5
Renal function: Plasma creatinine ≤ 1.5 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m²;
Inclusion criterion 8
Patients with active hepatitis B (defined as HBV DNA > 500 IU/mL) or hepatitis C (HCV RNA positive);
Exclusion criterion 4
HIV-positive patients or patients with a positive syphilis test;
Exclusion criterion 5
Primary malignant tumors that have been completely resected and have been in complete remission for ≥5 years;
Exclusion criterion 11
Patients of childbearing potential (both male and female) must agree to use reliable contraception methods (hormonal or barrier methods or abstinence) with their partner until at least 12 months after CAR-T cell infusion, and until two consecutive flow cytometry or PCR tests show no CAR-T cells in the body;
Inclusion criterion 12
Pregnant or breastfeeding female patients;
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06836505, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients who are diagnosed as relapsed/refractory neuroblastoma or relapsed/refractory desmoplastic small round cell tumors;
- Age 1-50 years, any gender;
- Agree to participate in the trial and sign a written informed consent form;
- Expected survival of ≥12 weeks;
- Karnofsky performance status (for patients ≥16 years) or Lansky performance status (for patients <16 years) (Appendix 1) must be at least 50;
- Good function of major organs:
- Liver function: ALT ≤ 5 times the upper limit of normal for the corresponding age, and bilirubin ≤ 2.0 mg/dL, except for patients with Gilbert-Meulengracht syndrome. Patients with Gilbert-Meulengracht syndrome who have bilirubin ≤ 3.0 times the upper limit of normal and direct bilirubin ≤ 1.5 times the upper limit of normal may be included;
- Renal function: Plasma creatinine ≤ 1.5 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m²;
- Pulmonary function: Oxygen saturation ≥ 95% in room air;
- Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 45%;
- Patients using the following medications must meet the following conditions:
Steroids: Steroid treatment doses must be stopped at least 2 weeks before CAR-T infusion. However, physiological replacement doses of steroids are allowed; Immunosuppressants: Any immunosuppressive drugs must be stopped at least 4 weeks before enrollment; Anti-proliferative treatments other than lymphodepleting chemotherapy within two weeks before infusion; CNS disease prophylaxis must be stopped 1 week prior to CAR-T infusion (e.g., intrathecal methotrexate injection);
- Patients of childbearing potential (both male and female) must agree to use reliable contraception methods (hormonal or barrier methods or abstinence) with their partner until at least 12 months after CAR-T cell infusion, and until two consecutive flow cytometry or PCR tests show no CAR-T cells in the body;
- If the subject cannot provide suitable T cells for CAR-T preparation, T cells from a healthy donor may be collected for preparation.
Exclusion Criteria:
- Patients with any of the following items will not be enrolled in this study:
- Patients with increased intracranial pressure or altered consciousness;
- Patients who have received radiation therapy within 2 weeks prior to infusion;
- Patients with active hepatitis B (defined as HBV DNA > 500 IU/mL) or hepatitis C (HCV RNA positive);
- HIV-positive patients or patients with a positive syphilis test;
- Patients with uncontrolled acute life-threatening bacterial, viral, or fungal infections (e.g., positive blood cultures within ≤72 hours before infusion);
- Patients with unstable angina and/or myocardial infarction within 6 months prior to screening;
- Patients with a history of or concurrent malignancies, except for the following conditions:
- Basal cell carcinoma or squamous cell carcinoma that has been adequately treated (sufficient wound healing required before study enrollment);
- Carcinoma in situ of the cervix or breast that has been cured, with no signs of recurrence for at least 3 years before the study;
- Primary malignant tumors that have been completely resected and have been in complete remission for ≥5 years;
- Pregnant or breastfeeding female patients;
- Patients with uncontrolled arrhythmias that have not been managed medically;
- Patients who need oral anticoagulation therapy within 1 week before CAR-T cell infusion;
- Patients with active neuroautoimmune or inflammatory diseases (e.g., Guillain-Barré syndrome, amyotrophic lateral sclerosis);
- Other conditions deemed inappropriate for participation in the clinical study by the investigator.
Patients enrolled in the clinical study must meet the inclusion criteria and not meet the exclusion criteria.
Quoted from ClinicalTrials.gov, NCT06836505, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06836505, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.